National Wealth Management Group LLC Buys New Holdings in Eli Lilly and Company (NYSE:LLY)

National Wealth Management Group LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, Holdings Channel.com reports. The fund purchased 451 shares of the company’s stock, valued at approximately $263,000.

A number of other large investors also recently modified their holdings of LLY. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at $35,000. Optiver Holding B.V. purchased a new stake in Eli Lilly and Company during the 3rd quarter worth $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now directly owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Bank of America increased their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Truist Financial reaffirmed a “buy” rating and set a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $12.11 during mid-day trading on Tuesday, hitting $743.44. 856,532 shares of the stock traded hands, compared to its average volume of 3,035,355. The company’s 50-day simple moving average is $763.83 and its 200-day simple moving average is $662.78. The firm has a market cap of $706.39 billion, a price-to-earnings ratio of 127.57, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $370.68 and a twelve month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm earned $2.09 EPS. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.